Vcanbio Cell & Gene Engineering Corp Ltd (600645) — Cash Flow-to-Debt Ratio
Vcanbio Cell & Gene Engineering Corp Ltd (600645) has a Cash Flow-to-Debt Ratio of 0.07x as of September 2025, meaning its operating cash flow of CN¥103.70 Million could theoretically repay 0% of its total liabilities (CN¥1.56 Billion) in one year. See cash generation quality of Vcanbio Cell & Gene Engineering Corp Ltd to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Vcanbio Cell & Gene Engineering Corp Ltd Cash Flow-to-Debt Ratio (1998–2025)
Historical debt coverage capacity for Vcanbio Cell & Gene Engineering Corp Ltd across 28 annual periods. Also explore 600645 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Vcanbio Cell & Gene Engineering Corp Ltd (1998–2025)
Year-by-year debt coverage analysis for Vcanbio Cell & Gene Engineering Corp Ltd. For market capitalisation and broader financial context, see Vcanbio Cell & Gene Engineering Corp Ltd (600645) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.20x | CN¥313.63 Million | CN¥1.54 Billion | ▲ +13.7% |
| 2024 | 0.18x | CN¥285.19 Million | CN¥1.59 Billion | ▼ -3.3% |
| 2023 | 0.19x | CN¥299.02 Million | CN¥1.61 Billion | ▲ +15.5% |
| 2022 | 0.16x | CN¥261.89 Million | CN¥1.63 Billion | ▼ -24.9% |
| 2021 | 0.21x | CN¥320.96 Million | CN¥1.50 Billion | ▲ +20.5% |
| 2020 | 0.18x | CN¥244.35 Million | CN¥1.38 Billion | ▲ +4.9% |
| 2019 | 0.17x | CN¥241.49 Million | CN¥1.43 Billion | ▲ +89.7% |
| 2018 | 0.09x | CN¥130.08 Million | CN¥1.46 Billion | ▲ +73.3% |
| 2017 | 0.05x | CN¥70.27 Million | CN¥1.37 Billion | ▼ -55.2% |
| 2016 | 0.11x | CN¥143.67 Million | CN¥1.25 Billion | ▲ +1492.5% |
| 2015 | 0.01x | CN¥8.17 Million | CN¥1.13 Billion | ▼ -95.9% |
| 2014 | 0.18x | CN¥221.45 Million | CN¥1.26 Billion | ▲ +30.9% |
| 2013 | 0.13x | CN¥110.72 Million | CN¥824.89 Million | ▲ +81.5% |
| 2012 | 0.07x | CN¥70.41 Million | CN¥951.88 Million | ▼ -61.2% |
| 2011 | 0.19x | CN¥110.44 Million | CN¥578.70 Million | ▼ -42.8% |
| 2010 | 0.33x | CN¥175.93 Million | CN¥527.56 Million | ▲ +23.0% |
| 2009 | 0.27x | CN¥124.92 Million | CN¥460.71 Million | ▼ -11.8% |
| 2008 | 0.31x | CN¥121.60 Million | CN¥395.43 Million | ▲ +11.0% |
| 2007 | 0.28x | CN¥111.68 Million | CN¥403.23 Million | ▲ +43.9% |
| 2006 | 0.19x | CN¥76.12 Million | CN¥395.35 Million | ▼ -26.6% |
| 2005 | 0.26x | CN¥84.69 Million | CN¥322.85 Million | ▲ +13.1% |
| 2004 | 0.23x | CN¥57.76 Million | CN¥248.95 Million | ▲ +50.7% |
| 2003 | 0.15x | CN¥41.74 Million | CN¥271.07 Million | ▲ +318.8% |
| 2002 | -0.07x | CN¥-14.75 Million | CN¥209.59 Million | ▲ +62.4% |
| 2001 | -0.19x | CN¥-68.84 Million | CN¥367.31 Million | ▼ -244.5% |
| 2000 | 0.13x | CN¥31.71 Million | CN¥244.41 Million | ▲ +670.6% |
| 1999 | 0.02x | CN¥4.13 Million | CN¥245.24 Million | ▲ +113.4% |
| 1998 | -0.13x | CN¥-32.14 Million | CN¥256.69 Million | — |